Trial Profile
Curative effect and adverse events in patients with advanced sarcoma treated with Apatinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2016
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Breast cancer; Chondrosarcoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology